India · English
Granules India expecting sole first to file status on Ruxolitinib Extended-Release Tablets
If confirmed by the FDA and all applicable statutory and regulatory requirements are satisfied, first-to-file status may provide eligibility for 180 days of generic drug exclusivity under US law
Read the full report at The Hindu BusinessLine →
How 3 newsrooms ran it
3 of our sources carried this story over 4.9 hours. The Hindu BusinessLine filed first, at 16:12 IST. The headlines below are each outlet's own wording, in the order they published.
| Time IST | Outlet | Their headline |
|---|---|---|
| 16:12 | The Hindu BusinessLine | Granules India expecting sole first to file status on Ruxolitinib Extended-Release Tablets |
| 17:00 | The Hindu BusinessLine | Granules India expecting sole first to file status on Ruxolitinib Extended-Release Tablets |
| 21:08 | The Hindu BusinessLine | Granules India expecting sole first to file status on Ruxolitinib Extended-Release Tablets |
About this page
AKHBAARI groups the same story across publishers so you can see who is reporting it and how they differ. The summary above is machine-generated from the publisher's own feed text and is labelled as such. The full report stays with the publisher, who holds copyright in it. See our editorial policy.